^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD122 agonist

    Related drugs:
    16h
    GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Suspended, Mayo Clinic | Not yet recruiting --> Suspended
    Trial suspension
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab)
    10d
    Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer (clinicaltrials.gov)
    P1, N=3, Terminated, National Cancer Institute (NCI) | Phase classification: P1/2 --> P1
    Phase classification
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Proleukin (aldesleukin)
    11d
    GIANTS-1: A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors (clinicaltrials.gov)
    P2, N=15, Recruiting, GI Innovation, Inc.
    New P2 trial
    1m
    STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, City of Hope Medical Center | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    1m
    GI-102 Alone or in Combination With Pembrolizumab Before Surgery for the Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    Keytruda (pembrolizumab)
    1m
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Recruiting, Mayo Clinic | Trial completion date: Jan 2026 --> Apr 2030 | Trial primary completion date: Jan 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    2ms
    ProbeTILity: A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Curacell Holding AB | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    2ms
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    2ms
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    2ms
    Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    2ms
    Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    3ms
    Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=8, Terminated, Alaunos Therapeutics | N=180 --> 8 | Active, not recruiting --> Terminated; Funding
    Enrollment change • Trial termination • IO biomarker
    |
    Proleukin (aldesleukin)